No Detail Found!

Long-Term Clinical Outcomes of the Transcatheter Aortic Valve System for Aortic Valve Stenosis

Author(s)
Zijia Wu Department of Cardiology, Yulin First People's Hospital, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, Guangxi, China
Lulan Gao Department of Laboratory, Yulin First People's Hospital, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, Guangxi, China
Lei Chen Department of Cardiology, Yulin First People's Hospital, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, Guangxi, China
Zhihai Lin Department of Cardiology, Yulin First People's Hospital, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, Guangxi, China
Abstract
Objective: To evaluate the clinical safety and efficacy of the self-expanding transcatheter aortic valve system in Chinese patients with severe aortic stenosis (AS) during follow-up. Study Design: Observational study. Place and Duration of the Study:Department of Cardiology, Yulin First People's Hospital, The Sixth A liated Hospital of Guangxi Medical University, Yulin, Guangxi, China, from April 2020 to September 2022. Methodology: A retrospective analysis was conducted on 101 patients with severe symptomatic AS who underwent transcatheter aortic valve replacement (TAVR) using a self-expanding transcatheter aortic valve system. Inclusion criteria were patients with severe symptomatic AS at high surgical risk or with contraindications for traditional surgery. Exclusion criteria included active infections and untreated severe coronary artery stenosis. The primary endpoint of this study was the mortality rate or complications within one year after TAVR. Results: The average age of the cohort was 69.5 ± 7.9 years, with 39.6% (n = 40) being female. The average risk score according to the Society of Thoracic Surgeons was 3.5 ± 2.7%. At one-year follow-up, the all-cause or cardiovascular disease mortality rate was 7.9% (n = 8). Importantly, no reports of major stroke or coronary artery obstruction occurred during the one-year follow-up, and the prognosis of patients with bicuspid aortic valve and tricuspid valve stenosis was comparable. Conclusion: The studied transcatheter valve replacement system is a safe and e ective traetment option for Chinese patients with severe aortic valve stenosis. Future multicentre and larger-scale randomised controlled trials are needed to verify that the self-expanding system can provide long-term benefits.
Publication Details
Page(s) 372-376
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Aortic valve stenosis, Transcatheter aortic valve replacement, Self-expanding transcatheter aortic valve system
References
Avvedimento M,Tang GHL .2021 .Transcatheter aortic valve replacement (TAVR): Recent updates. Prog Cardiovasc Dis, 11 : 73-83.
Ozdemir E,Esin FK,Tuluce SY,Karaca M.,Liang Y,Wang W,Wang X,Hei F,Guan Y. .2021 .A single-center analysis of outcomes, risk factors, and new valves in Asian patients treated with early transcatheter aortic valve implantation. Cardiovasc Diagn Ther, 10(4) : 967-79.
Zhou D,Pan W,Wang J,Wu Y,Chen M,Modine T .2020 .VitaFlow" transcatheter valve system in the treatment of severe aortic stenosis: One-year results of a multicentre study. Catheter Cardiovasc Interv, 10(2) : 332-8.
Bax JJ,Delgado V,Hahn RT,Leipsic J,Min JK,Grayburn P .2018 .Transcatheter aortic valve replacement role of multimodality imaging in common and complex clinical scenarios. Jacc-Cardiovascular Imaging, 10(1 Pt 1) : 124-39.
Feldman TE,Reardon MJ,Rajagopal V,Makkar RR,Bajwa TK,Kleiman NS .2017 .E ect of mechanically expandedvs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: The REPRISE III randomized clinical trial. JAMA, 19132(1) : 27-37.
Forrest JK,Kaple RK,Tang GHL,Yakubov SJ,Nazif TM,Williams MR .2020 .Three generations of self-expanding transcatheter aortic valves: A report from the STS/ACC TVT registry. JACC Cardiovasc Interv, 13(2) : 170-9.
.2019 .. , 08 : .
Sinning JM,Sedaghat A.,Choosing A. .2018 .a self-expanding transcatheter heart valve in 2018: Is it worth it to ". Go PRO"? JACC Cardiovasc Interv, 08(22) : 2323-5.
Kalogeras K,Ruparelia N,Kabir T,Jabbour R,Naganuma T,Vavuranakis M .2020 .Comparison of the self-expanding evolut-PRO transcatheter aortic valve to its predecessor evolut-R in the real world multicentre ATLAS registry. Int J Cardiol, 02 : 120-5.
Ravaux JM,Van Kuijk SMJ,Di Mauro M,Vernooy K,Bidar E,Van't Hof AW .2022 .Incidence and predictors of permanent pacemaker implantation after transcatheter aortic valve procedures: Data of the netherlands heart registration (NHR). J Clin Med, 10(3) : 560.
Li YM,Xiong TY,Xu K,Fang ZF,Jiang L,Jin J .0000000000001882 .Characteristics and outcomes following transcatheter aortic valve replacement in China: A report from China aortic valve transcatheter replacement registry (CARRY). Chin Med J (Engl), 10(22) : 2678-84.
Yoon SH,Lefevre T,Ahn JM,Perlman GY,Dvir D,Latib A .2016 .Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol, 06(11) : 1195-205.
Tchetche D,van Gils L,Parma R,Ochala A,Lefevre T .2019 .Bicuspid aortic valve anatomy and relationship with devices: The BAVARD multicentre registry. Circ Cardiovasc Interv, 10(1) : .
0

Citations

0

Downloads

171

Views